Recordati (REC) Q3 2024 earnings summary

Executive summary

• Net revenue for the first nine months of 2024 reached €1,743.1 million, up 12.0% year-over-year, with strong growth in both Specialty & Primary Care and Rare Diseases segments.

• EBITDA rose 11.8% to €665.7 million, maintaining a 38.2% margin, reflecting robust operating leverage.

• Adjusted net income increased 9.5% to €445.4 million, with reported net income up 11.1% to €338.4 million.

• Free cash flow was €434.3 million, up €42.5 million from the prior year, with leverage just below 1.6x EBITDA.

• Announced agreement to acquire global rights to Enjaymo® from Sanofi for $825 million upfront plus up to $250 million in milestones, expected to close by year-end 2024.

Financial highlights

• Net revenue: €1,743.1 million (+12.0% vs. 9M 2023); EBITDA: €665.7 million (+11.8%); margin at 38.2%.

• Adjusted net income: €445.4 million (+9.5%); net income: €338.4 million (+11.1%).

• Free cash flow: €434.3 million (+10.8% vs. 9M 2023); net debt at €1,317.3 million, leverage just below 1.6x EBITDA.

• Gross margin: 68.1% (gross profit €1,186.9 million); adjusted gross margin: 69.7%.

• SG&A: €470.7 million (27.0% of revenue); R&D: €204.8 million (11.8% of revenue).

Outlook and guidance

• FY 2024 revenue target confirmed at €2,300–2,340 million (+12.4% YoY), EBITDA €845–865 million (margin ~37%), adjusted net income €560–580 million.

• Minimal contribution from Enjaymo® expected in 2024; significant impact from 2025 onward, with projected revenue above €150 million and peak sales €250–300 million.

• 2025 targets to be confirmed in February; business performing in line with previous guidance.

• FX headwind of about 2% expected for the year, mainly from Turkish lira devaluation.